Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach
Abstract
The rising incidence of antimicrobial resistance (AMR) has threatened global public health with a high mortality rate. In parallel, the de-incentivization for further investment, regulatory constraints, and overuse/misuse of antibiotics have accelerated the progression of AMR. Together, these factors have contributed to the declining efficacy of a wide spectrum of antibiotics and the increasing prevalence of drug resistance that outpaced AMR-specific drug development. More importantly, even with substantial historical investments in antibiotic discovery over several decades, the development of clinically actionable, novel antibiotics has remained limited. In this article, we present the challenges of addressing AMR and outline emerging strategies that may reduce its burden. While advanced therapies, including bacteriophage therapy, have demonstrated promising results, complementary strategies that integrate emerging technologies and engage diverse stakeholders are needed. Building on this vision, we propose the potential role of AI-powered platforms in supporting and accelerating AMR-specific drug development alongside a community-driven approach that engages scientists, policymakers, health economists, clinicians, and patients to help address existing scientific and translational challenges. Furthermore, this article offers an inclusive strategy with key considerations, including educational and public health interventions, government-led programs, and health economics,…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.